Formulary Watch |

The FDA would like to see additional data on clinical benefit for patients with anal cancer.

Angiotensin receptor blockers may be less likely to cause side effects than ACE inhibitors.

Current drug shortages based on FDA data, prepared by Formulary Watch.

Keytruda gets a full approval in endometrial cancer; while Xeljanz will miss another PDUFDA date.

When Medicare D plans do provide coverage for first generics, they are often placed on non-generic tiers.

The FDA had approved Kadmon's therapy for graft-versus-host disease July 16.

The therapy is approved for both adults and children.

Azstarys is approved to treat patients 6 years and older.

Most of the suspected cases of myocarditis developed after the second dose of the vaccine and were among younger males.

The company’s stock began dropping on Tuesday with analyst expectation the FDA will issue a Complete Response Letter for tenapanor, its chronic kidney disease therapy.

Eight out of 10 covered U.S. commercial lives now have access to the H. pylori therapy.

This research sought to understand the relationship of prior medication exposure, existing health conditions, and COVID-19 outcomes using data from the American Heart Association’s COVID-19 Cardiovascular Disease Registry.

Current drug shortages based on FDA data, prepared by Formulary Watch.

FDA staff raised safety concerns ahead of the advisory panel hearing.

Merck has submitted the data from the study KEYNOTE-522 to the FDA for review.

Committee members raised safety concerns about FibroGen/AstraZeneca’s oral therapy roxadustat.

After generic entry, Zytiga’s market share fell to about 14% and monthly net sales across the entire market fell 85%.

New analysis suggests that even with rebates, the new Alzheimer’s therapy could have implications for Medicaid drug spending.

A permanent code is expected in the third quarter of 2021.

The therapy for opioid-induced constipation has no restrictions on an unidentified national formulary that serves these Blues plans.

The new indication provides a subcutaneous option for multiple myeloma that can be administrated in minutes, rather than hours.